Search

Remdesivir

[L18438] Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc.[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … [L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020,[L13236] remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22

Buclizine

It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.

Sevabertinib

[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain

Edaravone

[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.

Zinc sulfate

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Telisotuzumab vedotin

[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.

Bamlanivimab

[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … [A224044, L20974] It is set to enter phase 3 clinical trials.

Benzyl alcohol

Voriconazole

[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660] … Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.

Albutrepenonacog alfa

[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.